Browse KIF23

Summary
SymbolKIF23
Namekinesin family member 23
Aliases MKLP1; MKLP-1; KNSL5; kinesin-like 5 (mitotic kinesin-like protein 1); CHO1; Mitotic kinesin-like protein 1; ......
Chromosomal Location15q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus. Cytoplasm, cytoskeleton, spindle. Midbody, Midbody ring Note=Localizes to the interzone of mitotic spindles. Detected at the midbody during later stages of mitotic cytokinesis.
Domain PF00225 Kinesin motor domain
PF16540 Arf6-interacting domain of mitotic kinesin-like protein 1
Function

Component of the centralspindlin complex that serves as a microtubule-dependent and Rho-mediated signaling required for the myosin contractile ring formation during the cell cycle cytokinesis. Essential for cytokinesis in Rho-mediated signaling. Required for the localization of ECT2 to the central spindle. Plus-end-directed motor enzyme that moves antiparallel microtubules in vitro.

> Gene Ontology
 
Biological Process GO:0000022 mitotic spindle elongation
GO:0000070 mitotic sister chromatid segregation
GO:0000226 microtubule cytoskeleton organization
GO:0000281 mitotic cytokinesis
GO:0000819 sister chromatid segregation
GO:0000910 cytokinesis
GO:0000912 assembly of actomyosin apparatus involved in cytokinesis
GO:0000915 actomyosin contractile ring assembly
GO:0002478 antigen processing and presentation of exogenous peptide antigen
GO:0002495 antigen processing and presentation of peptide antigen via MHC class II
GO:0002504 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II
GO:0006890 retrograde vesicle-mediated transport, Golgi to ER
GO:0007018 microtubule-based movement
GO:0007051 spindle organization
GO:0007052 mitotic spindle organization
GO:0007059 chromosome segregation
GO:0007067 mitotic nuclear division
GO:0010970 transport along microtubule
GO:0019882 antigen processing and presentation
GO:0019884 antigen processing and presentation of exogenous antigen
GO:0019886 antigen processing and presentation of exogenous peptide antigen via MHC class II
GO:0030705 cytoskeleton-dependent intracellular transport
GO:0030865 cortical cytoskeleton organization
GO:0030866 cortical actin cytoskeleton organization
GO:0031032 actomyosin structure organization
GO:0032465 regulation of cytokinesis
GO:0032467 positive regulation of cytokinesis
GO:0032506 cytokinetic process
GO:0044837 actomyosin contractile ring organization
GO:0045787 positive regulation of cell cycle
GO:0047496 vesicle transport along microtubule
GO:0048002 antigen processing and presentation of peptide antigen
GO:0048193 Golgi vesicle transport
GO:0051225 spindle assembly
GO:0051231 spindle elongation
GO:0051255 spindle midzone assembly
GO:0051256 mitotic spindle midzone assembly
GO:0051302 regulation of cell division
GO:0051640 organelle localization
GO:0051648 vesicle localization
GO:0051650 establishment of vesicle localization
GO:0051656 establishment of organelle localization
GO:0051781 positive regulation of cell division
GO:0061640 cytoskeleton-dependent cytokinesis
GO:0072383 plus-end-directed vesicle transport along microtubule
GO:0072384 organelle transport along microtubule
GO:0072386 plus-end-directed organelle transport along microtubule
GO:0090068 positive regulation of cell cycle process
GO:0090307 mitotic spindle assembly
GO:0098813 nuclear chromosome segregation
GO:0099518 vesicle cytoskeletal trafficking
GO:1902850 microtubule cytoskeleton organization involved in mitosis
Molecular Function GO:0003774 motor activity
GO:0003777 microtubule motor activity
GO:0008017 microtubule binding
GO:0015631 tubulin binding
GO:0016887 ATPase activity
Cellular Component GO:0005813 centrosome
GO:0005819 spindle
GO:0005871 kinesin complex
GO:0005874 microtubule
GO:0005875 microtubule associated complex
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0030055 cell-substrate junction
GO:0030496 midbody
GO:0045171 intercellular bridge
GO:0072686 mitotic spindle
GO:0097149 centralspindlin complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-6811434: COPI-dependent Golgi-to-ER retrograde traffic
R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-983231: Factors involved in megakaryocyte development and platelet production
R-HSA-8856688: Golgi-to-ER retrograde transport
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-6811442: Intra-Golgi and retrograde Golgi-to-ER traffic
R-HSA-983189: Kinesins
R-HSA-68886: M Phase
R-HSA-2132295: MHC class II antigen presentation
R-HSA-199991: Membrane Trafficking
R-HSA-68884: Mitotic Telophase/Cytokinesis
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolKIF23
Namekinesin family member 23
Aliases MKLP1; MKLP-1; KNSL5; kinesin-like 5 (mitotic kinesin-like protein 1); CHO1; Mitotic kinesin-like protein 1; ......
Chromosomal Location15q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between KIF23 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolKIF23
Namekinesin family member 23
Aliases MKLP1; MKLP-1; KNSL5; kinesin-like 5 (mitotic kinesin-like protein 1); CHO1; Mitotic kinesin-like protein 1; ......
Chromosomal Location15q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of KIF23 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolKIF23
Namekinesin family member 23
Aliases MKLP1; MKLP-1; KNSL5; kinesin-like 5 (mitotic kinesin-like protein 1); CHO1; Mitotic kinesin-like protein 1; ......
Chromosomal Location15q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of KIF23 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0320.913
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3770.794
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3330.764
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1460.688
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2360.881
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0350.986
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0360.927
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2270.881
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2760.858
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2290.781
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3880.752
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.4690.000125
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of KIF23 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolKIF23
Namekinesin family member 23
Aliases MKLP1; MKLP-1; KNSL5; kinesin-like 5 (mitotic kinesin-like protein 1); CHO1; Mitotic kinesin-like protein 1; ......
Chromosomal Location15q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KIF23. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolKIF23
Namekinesin family member 23
Aliases MKLP1; MKLP-1; KNSL5; kinesin-like 5 (mitotic kinesin-like protein 1); CHO1; Mitotic kinesin-like protein 1; ......
Chromosomal Location15q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KIF23. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KIF23.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolKIF23
Namekinesin family member 23
Aliases MKLP1; MKLP-1; KNSL5; kinesin-like 5 (mitotic kinesin-like protein 1); CHO1; Mitotic kinesin-like protein 1; ......
Chromosomal Location15q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KIF23. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolKIF23
Namekinesin family member 23
Aliases MKLP1; MKLP-1; KNSL5; kinesin-like 5 (mitotic kinesin-like protein 1); CHO1; Mitotic kinesin-like protein 1; ......
Chromosomal Location15q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of KIF23 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolKIF23
Namekinesin family member 23
Aliases MKLP1; MKLP-1; KNSL5; kinesin-like 5 (mitotic kinesin-like protein 1); CHO1; Mitotic kinesin-like protein 1; ......
Chromosomal Location15q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between KIF23 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolKIF23
Namekinesin family member 23
Aliases MKLP1; MKLP-1; KNSL5; kinesin-like 5 (mitotic kinesin-like protein 1); CHO1; Mitotic kinesin-like protein 1; ......
Chromosomal Location15q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting KIF23 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.